- Home
- SNX vs INM Comparison
SNX vs INM Comparison
Compare SNX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- INM
- Stock Information
- Founded
- SNX 1980
- INM 1981
- Country
- SNX United States
- INM Canada
- Employees
- SNX N/A
- INM N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- INM Health Care
- Exchange
- SNX Nasdaq
- INM Nasdaq
- Market Cap
- SNX 11.2B
- INM 3.2M
- IPO Year
- SNX 2003
- INM N/A
- Fundamental
- Price
- SNX $140.96
- INM $2.78
- Analyst Decision
- SNX Strong Buy
- INM
- Analyst Count
- SNX 9
- INM 0
- Target Price
- SNX $140.89
- INM N/A
- AVG Volume (30 Days)
- SNX 1.1M
- INM 5.8M
- Earning Date
- SNX 06-24-2025
- INM 05-12-2025
- Dividend Yield
- SNX 1.25%
- INM N/A
- EPS Growth
- SNX 19.95
- INM N/A
- EPS
- SNX 8.55
- INM N/A
- Revenue
- SNX $60,007,297,000.00
- INM $4,920,990.00
- Revenue This Year
- SNX $4.63
- INM N/A
- Revenue Next Year
- SNX $4.23
- INM N/A
- P/E Ratio
- SNX $16.53
- INM N/A
- Revenue Growth
- SNX 6.60
- INM N/A
- 52 Week Low
- SNX $92.23
- INM $1.72
- 52 Week High
- SNX $145.10
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- SNX 68.74
- INM 47.36
- Support Level
- SNX $140.25
- INM $2.69
- Resistance Level
- SNX $144.17
- INM $3.28
- Average True Range (ATR)
- SNX 2.92
- INM 0.26
- MACD
- SNX 0.08
- INM -0.03
- Stochastic Oscillator
- SNX 69.31
- INM 8.79
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.